OverviewSuggest Edit

Dicerna Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. Dicerna’s entire drug pipeline is generated from its proprietary RNA interference (RNAi) technology platform, which is believed to improve upon existing RNAi technologies. RNAi is a highly potent and specific mechanism for silencing the activity of a targeted disease-driving gene. Dicerna’s discovery approach is based on proprietary double-stranded RNA molecules which the Company believes maximizes RNAi potency.
TypePublic
Founded2007
HQCambridge, MA, US
Websitedicerna.com
Employee Ratings4.6

Latest Updates

Employees (est.) (Dec 2018)78(+78%)
Job Openings30
Revenue (FY, 2020)$164.3 M(+588%)
Share Price (Apr 2021)$28.7
Cybersecurity ratingBMore

Key People/Management at Dicerna Pharmaceuticals

Douglas M. Fambrough

Douglas M. Fambrough

President and Chief Executive Officer
Martin Freed

Martin Freed

Independent Director
Patrick Gray

Patrick Gray

Independent Director
Bob D. Brown

Bob D. Brown

Chief Scientific Officer, Executive Vice President of R&D
Shreeram Aradhye

Shreeram Aradhye

Executive Vice President and Chief Medical Officer
Marc Kozin

Marc Kozin

Independent Director
Show more

Dicerna Pharmaceuticals Office Locations

Dicerna Pharmaceuticals has offices in Cambridge and Lexington
Cambridge, MA, US (HQ)
87 Cambridgepark Dr
Lexington, MA, US
33 Hayden Ave
Show all (2)

Dicerna Pharmaceuticals Financials and Metrics

Dicerna Pharmaceuticals Revenue

Dicerna Pharmaceuticals's revenue was reported to be $164.31 m in FY, 2020
USD

Revenue (FY, 2020)

164.3m

Net income (FY, 2020)

(112.7m)

EBIT (FY, 2020)

(113.2m)

Market capitalization (23-Apr-2021)

2.2b

Closing stock price (23-Apr-2021)

28.7

Cash (31-Dec-2020)

126.0m
Dicerna Pharmaceuticals's current market capitalization is $2.2 b.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

184.0k295.0k2.3m6.2m23.9m164.3m

Revenue growth, %

60%

General and administrative expense

15.6m19.2m18.3m25.9m21.7m42.8m72.1m

R&D expense

29.5m44.0m41.7m37.0m45.7m109.3m205.4m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

184.0k162.0k133.0k252.0k474.0k1.5m1.5m3.1m5.7m8.0m34.0m40.4m48.9m

General and administrative expense

2.8m4.4m3.7m5.4m4.5m4.9m4.5m4.7m4.3m5.5m6.3m6.7m7.5m4.8m5.4m9.7m8.8m10.6m16.0m20.6m17.0m

R&D expense

5.3m6.8m7.5m8.7m11.9m12.1m11.3m11.0m10.1m8.9m9.3m9.0m9.9m10.3m11.7m21.6m22.8m30.1m43.2m53.4m54.8m

Operating expense total

8.1m11.2m11.2m14.1m16.4m17.0m15.7m15.7m14.4m14.4m15.6m15.7m17.4m15.1m17.0m31.3m31.7m40.7m59.2m73.9m71.8m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

26.1m56.1m20.9m68.8m54.2m152.8m126.0m

Accounts Receivable

254.7m805.4k100.0m34.7m

Prepaid Expenses

3.3m2.9m6.9m14.4m

Inventories

1.2m1.5m2.0m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

133.8m77.7m31.8m22.6m25.9m52.9m27.6m29.2m32.5m22.9m38.8m31.0m43.0m42.4m46.4m160.1m100.3m47.2m245.5m197.8m204.3m

Accounts Receivable

3.0m15.0m12.0k5.0m

Prepaid Expenses

906.0k1.0m856.0k1.4m1.7m1.7m1.2m1.5m1.8m2.7m3.0m3.9m2.4m3.7m3.1m2.2m5.0m4.7m8.6m12.5m12.7m

Current Assets

134.7m101.3m93.7m89.1m96.7m95.7m81.8m70.7m59.4m36.2m91.7m79.8m101.8m87.6m183.5m373.4m350.2m320.4m730.5m681.8m627.7m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(47.9m)(62.8m)(59.5m)(60.0m)(88.9m)(120.5m)(112.7m)

Depreciation and Amortization

848.0k727.0k840.0k778.0k1.3m

Inventories

(44.3m)

Accounts Payable

(97.0k)1.4m1.6m626.0k(1.2m)2.1m2.2m
USDQ1, 2014

Financial Leverage

1.1 x
Show all financial metrics

Dicerna Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

Dicerna Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Dicerna Pharmaceuticals Online and Social Media Presence

Embed Graph

Dicerna Pharmaceuticals News and Updates

Dicerna Pharmaceuticals Blogs

Dicerna to Report First Quarter 2021 Financial Results on May 6, 2021

Dicerna to Report First Quarter 2021 Financial Results on May 6, 2021 Content Import Thu, 04/29/2021 - 16:06 Dicerna to Report First Quarter 2021 Financial Results on May 6, 2021 Apr 29, 2021 This release is a backfill from a News Wire General …

Dicerna Sells OXLUMO™ (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million

– Dicerna To Receive $180 Million Upfront and Up to $60 Million in Potential Additional Milestone Payments – LEXINGTON, Mass. & NEW YORK --(BUSINESS WIRE)--Apr. 8, 2021-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Dicerna”) and Royalty Pharma plc (Nasdaq: RPRX) (“Royalty Pharma”) today

Dicerna’s GalXC-Plus™ RNAi Technology Delivers Target Knockdown Across CNS and to Specific CNS Cell Types in Preclinical Studies

Dicerna’s GalXC-Plus™ RNAi Technology Delivers Target Knockdown Across CNS and to Specific CNS Cell Types in Preclinical Studies Content Import Tue, 03/30/2021 - 10:50 Dicerna’s GalXC-Plus™ RNAi Technology Delivers Target Knockdown Across CNS and to Specific CNS Cell Types in Preclinical S…

Oligonucleotide and Precision Therapeutics (OPT) Virtual Congress

Oligonucleotide and Precision Therapeutics (OPT) Virtual Congress Matthew.Callan… Tue, 03/30/2021 - 10:26 Oligonucleotide and Precision Therapeutics (OPT) Virtual Congress Display "add to calendar" true Event Type Corporate Conference Call …

Dicerna to Present New GalXC-Plus™ Nonclinical CNS Data at Oligonucleotide and Precision Therapeutics Virtual Congress

Dicerna to Present New GalXC-Plus™ Nonclinical CNS Data at Oligonucleotide and Precision Therapeutics Virtual Congress Content Import Wed, 03/24/2021 - 07:31 Dicerna to Present New GalXC-Plus™ Nonclinical CNS Data at Oligonucleotide and Precision Therapeutics Virtual Congress Mar 24,…

Dicerna to Host Webinar on DCR-AUD Alcohol Use Disorder Candidate on March 18, 2021

Dicerna to Host Webinar on DCR-AUD Alcohol Use Disorder Candidate on March 18, 2021 Content Import Thu, 03/11/2021 - 07:31 Dicerna to Host Webinar on DCR-AUD Alcohol Use Disorder Candidate on March 18, 2021 Mar 11, 2021 This release is a backfill from a News Wire …
Show more

Dicerna Pharmaceuticals Frequently Asked Questions

  • When was Dicerna Pharmaceuticals founded?

    Dicerna Pharmaceuticals was founded in 2007.

  • Who are Dicerna Pharmaceuticals key executives?

    Dicerna Pharmaceuticals's key executives are Douglas M. Fambrough, Martin Freed and Patrick Gray.

  • How many employees does Dicerna Pharmaceuticals have?

    Dicerna Pharmaceuticals has 78 employees.

  • What is Dicerna Pharmaceuticals revenue?

    Latest Dicerna Pharmaceuticals annual revenue is $164.3 m.

  • What is Dicerna Pharmaceuticals revenue per employee?

    Latest Dicerna Pharmaceuticals revenue per employee is $2.1 m.

  • Who are Dicerna Pharmaceuticals competitors?

    Competitors of Dicerna Pharmaceuticals include TxCell, Urogen Pharma and Voltron Therapeutics.

  • Where is Dicerna Pharmaceuticals headquarters?

    Dicerna Pharmaceuticals headquarters is located at 87 Cambridgepark Dr, Cambridge.

  • Where are Dicerna Pharmaceuticals offices?

    Dicerna Pharmaceuticals has offices in Cambridge and Lexington.

  • How many offices does Dicerna Pharmaceuticals have?

    Dicerna Pharmaceuticals has 2 offices.